Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer

Journal of Clinical Oncology

Volumn 15, Issue 10, 1997, Pages 3214-3222

  Eastham, James A ^a   Kattan, Michael W ^a   Groshen, Susan ^a   Scardino, Peter T ^a   Rogers, Eamonn ^a   Carlton, C Eugene ^a   Lerner, Seth P ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; EARLY CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0030923392     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.10.3214     Document Type: Article

References (38)

1. Bagshaw MA, Kaplan ID, Cox RC: Radiation therapy for localized disease. Cancer 71:939-952, 1993 (suppl)
2. Shipley WU: Radical treatment with radiation of "early stage" prostate cancer: Impressive results with long-term follow-up. J Urol 152:1773-1774, 1994
3. Hanks GE, Hanlon A, Schultheiss T, et al: Early prostate cancer: National results of radiation treatment from patterns of care and radiation therapy oncology group studies with prospects for improvement with conformational radiation and adjuvant androgen deprivation. J Urol 152:1775-1780, 1994
4. Catalona WJ, Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152:1837-1842, 1994
5. Zincke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152:1850-1857, 1994
6. Whitmore WF Jr, Adolfsson J, Steineck G: Conservative management of localized prostate cancer. Am J Clin Oncol 15:446-452, 1992
7. Fleming C, Wasson JH, Albertson PC, et al: A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269:2650-2658, 1993
8. Adolfsson J, Rönström L, Löwhagen T, et al: Deferred treatment of clinically localized low grade prostate cancer: Experience from prospective series at Karolinska Hospital. J Urol 152:1757-1760, 1994
9. Chodak GW, Thisted RA, Gerber GS, et al: Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242-248, 1994
10. Belt E, Schroeder FH: Total perineal prostatectomy for carcinoma of the prostate. J Urol 107:91-96, 1972
11. Lee RJ, Sause WT: Surgically staged patients with prostatic carcinoma treated with definitive radiation therapy. Fifteen-year results. Urology 43:640-644, 1994
12. Bagshaw MA: Radiation therapy for cancer of the prostate, in Skinner DG, Lieskovsky G (eds): Diagnosis and Management of Genitourinary Cancer. Philadelphia, PA, Saunders, 1988, pp 425-445
13. Lemer SP, Seale-Hawkins C, Carlton CE Jr, et al: The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 146:1040-1045, 1991
14. Whitmore WF Jr: Hormone therapy in prostatic cancer. Am J Med 21:697-713, 1956
15. Jewett HJ: The present status of radical prostatectomy for stage A and B prostate cancer. Urol Clin North Am 2:105-124, 1975
16. Miller RG: Survival Analysis. New York, NY, Wiley, 1981, pp 98, 117
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 34:585-612, 1976
19. Gaynor JJ, Fever EJ, Tan CG, et al: On the use of cause-specific failure and conditional failure probabilities: example from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
20. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
21. Gervasi LA, Mata JA, Seale C, et al: The prognostic significance of the extent of nodal metastases in prostatic cancer. J Urol 142:332-336, 1989
22. Zincke H, Utz DC: Observations on surgical management of carcinoma of the prostate with limited nodal metastases. Urology 24:137-145, 1984
23. Catalona WJ, Smith DS, Ratliff TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270:948-954, 1993
24. Danella JF, deKernion JB, Smith RB, et al: The contemporary incidence of lymph node metastases in prostate cancer: Implication for laparoscopic lymph node dissection. J Urol 149:1488-1491, 1993
25. Zagars GK, von Eschenbach AC, Ayala AG: Prognostic factors in prostate cancer - Analysis of 874 patient treated with radiation therapy. Cancer 72:1709-1725, 1993
26. Bagshaw MA: Potential for radiotherapy alone in prostatic cancer. Cancer 55:2079-2085, 1985
27. Whitmore WF Jr, Hilaris B, Sogani P, et al: Interstitial irradiation using 1-125 seeds. Prog Clin Biol Res 243B:177-195, 1987
28. Pilepich MV, Krall JM, Al-Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the radiation therapy oncology group. Urology 45:616-623, 1995
29. Ennis RD, Peschel RE: Radiation therapy for prostate cancer: Long-term results and implications for future advances. Cancer 72:2644-2650, 1993
30. Bagshaw, MA, Cox RS, Hancock SL: Control of prostate cancer with radiotherapy: Long-term results. J Urol 152:1781-1785, 1994
31. Bagshaw MA, Ray GR, Cox RS: Selecting initial therapy for prostate cancer. Cancer 60:521-525, 1987 (suppl 3)
32. Hanks GE, Asbell S, Krall JM, et al: Outcome for lymph node dissection negative T-1b, T-2 (A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int J Radiat Oncol Biol Phys 21:1099-1103, 1991
33. Pepe MS, Mori M: Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12:737-751, 1993
34. Stamey TA, Kabalin JN, Ferrari M: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate III: Radiation treated patients. J Urol 141:1084-1089, 1989
35. Zagars GK: Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys 23:47-53, 1992
36. Zagars GK: Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol Clin North Am 20:737-747, 1993
37. Geist RW: Reference range for prostate specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate. Urology 45:1016-1021, 1995
38. Goad JR, Chang S-J, Ohori M, et al: PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am 20:727-736, 1993